GHRP-2

What GHRP-2 does

GHRP-2 raises growth hormone and can increase hunger. Japan uses pralmorelin for supervised GH testing. Human studies mostly measured hormone responses, not lasting muscle or recovery benefits. Cortisol, prolactin and blood sugar can change. Long-term wellness use and online product quality remain poorly studied.

• In small controlled studies, it increased hunger and how much people ate. (Studied in a trial)
• In a study of adults, a supervised one-time IV test helped tell severe growth hormone deficiency apart from normal. (Studied in a trial)
• In a small clinic study, a mix including it raised IGF-1, but muscle gain and fat loss were not measured well. (Studied in a trial)

Uses in the sources

• Studied for GH stimulation testing; pralmorelin has a Japanese diagnostic approval, not an FDA/EMA dose label. (Studied in a trial) (source)
• SC infusion increased food intake in small, controlled studies of lean and obese adults. (Studied in a trial) (source)
• A clinician-published combination raised IGF-1; muscle gain and fat loss were not measured adequately. (Clinician-published) (source)

GHRP-2 dosage

Typical reported dose: 200 mcg three times a day, with CJC no DAC

• Single supervised GH test: 100 mcg IV once after overnight fasting; blood sampled for up to 2 hours. once for diagnostic testing, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV challenge: 1 mcg/kg: 1 mcg/kg IV once; no titration. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV challenge with GHRH: GHRP-2 1 mcg/kg plus GHRH 1 mcg/kg IV once. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV challenge: 2 mcg/kg: 2 mcg/kg IV once; no chronic titration. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• Five-day SC study: 100 mcg SC once daily for 5 days; no titration. once daily, under the skin. Studied in a trial. Studied in: Adults in the cited study. (source)
• Continuous SC: 1 mcg/kg/hour: 1 mcg/kg/hour continuously by SC infusion for 30 days. continuous infusion at 1 mcg/kg/hour, under the skin. Studied in a trial. Studied in: Adults in the cited study. (source)

Highest studied: Highest retrieved fixed-dose SC three-times-daily human regimen was 100 mcg, with GHRP-6 and sermorelin..

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix GHRP-2

Comes as: Lyophilized powder in community vials, Japanese 100 mcg diagnostic vial, Nasal spray and oral preparations studied separately.

Mixed with: Community replies use bacteriostatic water. The Japanese diagnostic vial uses 10 mL saline immediately before IV use..

Common vial sizes: 5 mg. Common water amounts: 2.5 mL.

• The 5 mg/2.5 mL example is community-reported, not the Japanese diagnostic formulation.
• The Japanese product is kept below 10°C without freezing and protected from light; use promptly after mixing.
• Japanese label stability information cannot be transferred to unknown community formulations.

Before mixing: Community users refrigerate vials; no validated shelf life for unregulated products was found.

After mixing: Users refrigerate mixed vials. No general home-vial beyond-use period is established.

GHRP-2 side effects and risks

Reported side effects

• Feeling hot: 16.0% in the Japanese diagnostic label; not a rate for chronic SC use., mild (source)
• Stomach rumbling: At least 5% in the diagnostic label; the exact band boundary is not given., mild (source)
• Low blood pressure or stomach upset: Each listed at 0.1% to under 5% in diagnostic use; this spans several frequency bands., moderate (source)
• Increased hunger: Food intake +10.2% and +33.5% at the lower and higher infusion rates versus placebo., mild (source)
• Cortisol or prolactin increase: unknown, moderate (source)
• High glucose, infection or pancreatitis reports: FDA reports these events and ICU deaths; causality and incidence are not established., serious (source)
• Swelling and joint discomfort: unknown, moderate (source)

Stop and get help if

• Trouble breathing, tongue swelling, fainting or widespread hives: Stop and get emergency care now.
• Sudden severe headache, new vision loss or repeated vomiting: Get emergency assessment now; a pituitary or pressure problem must be excluded.
• Chest pain, severe breathlessness or collapse: Call emergency services now.
• Persistent severe abdominal pain or repeated vomiting: Stop and get urgent medical assessment.
• Confusion, seizure, or low blood sugar that does not resolve: Get emergency help now; do not drive.
• Fever with a hot, spreading, painful injection site: Get urgent care for a possible injection infection.

Who should avoid it

• pregnant: The Japanese pralmorelin label contraindicates pregnancy or possible pregnancy.
• breastfeeding: Avoid while breastfeeding. Human infant exposure and safety are unknown.
• tryingToConceive: Avoid while trying to conceive. Human fertility and early-pregnancy safety are unknown.
• under18: Historical child studies do not support unsupervised use in minors.
• activeCancer: GH and IGF-1 are growth signals. Avoid with active cancer; this applies GH-treatment precautions to secretagogues.
• cancerHistory: Prior cancer needs a clinician review before raising GH or IGF-1. Recurrence risk with this compound is unknown.
• diabetes: GH-related changes can worsen insulin sensitivity. Review blood sugar control and medicines.
• heartCondition: Fluid retention may strain the heart. Heart-disease safety is not established for home-use schedules.
• uncontrolledBloodPressure: Review uncontrolled blood pressure before use. Fluid retention and pressure changes need assessment.
• kidneyDisease: Kidney-disease dose adjustments and repeated-dose safety are not established.
• liverDisease: Liver-disease dose adjustments and repeated-dose safety are not established.
• diabeticRetinopathy: Review proliferative eye disease before raising GH or IGF-1. This is a GH-class precaution.
• pancreatitisHistory: Review prior pancreatitis. GH-class safety concerns do not establish a risk rate for this compound.
• sleepApnea: Review sleep apnea and new swelling. GH-related tissue or fluid changes are a class concern.
• surgeryPlanned: Tell the surgical team about use and all stacks. Perioperative safety depends on the specific study setting.
• testedAthlete: WADA bans this compound at all times, including out of competition.
• other: Do not add a GH secretagogue when GH or IGF-1 is already excessive. Investigate the cause.
• other: A pituitary mass needs specialist review. GH testing and GH-raising drugs are not interchangeable.

Interactions

• Insulin and sulfonylureas: GH-class precaution: insulin sensitivity and medicine needs can change. Exact interaction trials for this peptide are lacking.
• Other GH secretagogues, GH, and IGF-1: Overlapping GH/IGF-1 effects can add hormone, swelling and blood sugar risks. Combination benefit is not established.
• Glucocorticoids and oral estrogen: These can change GH responses or IGF-1 interpretation. Do not change prescribed hormone replacement to alter a peptide response.
• Anticoagulants and antiplatelets: General injection precaution: blood thinners increase bleeding/bruising risk. A direct interaction with this peptide has not been established.
• Other pituitary diagnostic agents: The Japanese label says simultaneous diagnostic use lacks established safety; use requires a supervised test plan.

Product quality risks

• Unregulated products may have the wrong identity, dose or sterility. A purity percentage alone cannot establish injection safety.
• Studies identified glycine-modified GHRP-2, GHRP-6 and ipamorelin in black-market or seized preparations.
• No representative market-wide contamination or underdosing rate was found for this compound.

What to expect

At least 72 human research papers; some share participants. Small infusion studies found higher food intake at one meal, without testing lasting benefits.

Key studies

• Japanese adult GH test: A supervised 100 mcg IV test separated severe GH deficiency from healthy responses. (source)
• GHRP-2 versus GHRH: GHRP-2 released more GH than GHRH; synergy was not demonstrated at these doses. (source)
• GHRP-2 versus hexarelin: Both peptides stimulated other hormones as well as GH. (source)
• 100 mcg daily for five days: GH responses weakened over five days and IGF-1 did not rise. (source)
• Continuous SC infusion for 30 days: Continuous infusion sustained hormone changes; this does not validate intermittent self-injections. (source)
• Older adults: bolus and infusion: Dose pattern, route and pituitary reserve strongly affected the hormone response. (source)

GHRP-2 FAQ

• Is GHRP-2 FDA-approved? No FDA-approved product. Japan approves pralmorelin for GH testing. 503B Category 1 covers routes other than injection/nasal; those remain Category 2.
• How do people take it? Under the skin, three times daily. Source: reported by users, not an established dose.
• What's the difference between GHRP-2 and Sermorelin? GHRP-2: a peptide that releases growth hormone and can increase hunger. Sermorelin: an experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits. Why people pair them: the published clinician cohort used all three to raise IGF-1.
• Can I take it with Sermorelin with GHRP-6? The published clinician cohort used all three to raise IGF-1. No control group; safety and body-composition benefits were not established. Source: clinician-published. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Named on the 2026 list; prohibited in and out of competition.
• How long does a mixed vial last? Users refrigerate mixed vials. No general home-vial beyond-use period is established.